Treace Medical Concepts reported a 10% revenue decline to $47.2 million in Q1 2026 compared to the same period last year, with a net loss increasing to $18 million. Despite the loss, cash and marketable securities grew to $51.9 million, up $3.5 million from the previous quarter. The company launched its SuperBite™ Compression Screw System and expanded its patent portfolio, aiming to grow surgeon adoption and market share. Treace reaffirmed its 2026 revenue guidance of $202-$212 million and expects adjusted EBITDA losses between $4 million and $6 million, anticipating stronger growth in the latter half of the year.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
